These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9531870)

  • 1. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization.
    Surrey ES; Bower J; Hill DM; Ramsey J; Surrey MW
    Fertil Steril; 1998 Mar; 69(3):419-24. PubMed ID: 9531870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol.
    Schoolcraft W; Schlenker T; Gee M; Stevens J; Wagley L
    Fertil Steril; 1997 Jan; 67(1):93-7. PubMed ID: 8986690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a.
    Karacan M; Erkan H; Karabulut O; Sarikamiş B; Camlibel T; Benhabib M
    J Reprod Med; 2001 May; 46(5):485-9. PubMed ID: 11396377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.
    Gelety TJ; Pearlstone AC; Surrey ES
    Fertil Steril; 1995 Dec; 64(6):1074-80. PubMed ID: 7589655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study.
    Dantas ZN; Vicino M; Balmaceda JP; Asch RH; Stone SC
    Fertil Steril; 1994 Apr; 61(4):705-8. PubMed ID: 8150114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders.
    Padilla SL; Dugan K; Maruschak V; Shalika S; Smith RD
    Fertil Steril; 1996 Apr; 65(4):796-9. PubMed ID: 8654641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study.
    Ferrari B; Barusi L; Coppola F
    J Reprod Med; 2002 Feb; 47(2):137-43. PubMed ID: 11883353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization.
    Keltz MD; Gera PS; Skorupski J; Stein DE
    Fertil Steril; 2007 Aug; 88(2):350-3. PubMed ID: 17693328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis.
    Surrey ES; Silverberg KM; Surrey MW; Schoolcraft WB
    Fertil Steril; 2002 Oct; 78(4):699-704. PubMed ID: 12372443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and follicular fluid hormone levels during in vitro fertilization after short- or long-course treatment with a gonadotropin-releasing hormone agonist.
    Bo-Abbas YY; Martin KA; Liberman RF; Cramer DW; Barbieri RL
    Fertil Steril; 2001 Apr; 75(4):694-9. PubMed ID: 11287021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders--an observational pilot study.
    Mitri F; Behan LA; Murphy CA; Hershko-Klement A; Casper RF; Bentov Y
    Fertil Steril; 2016 Jan; 105(1):100-5.e1-6. PubMed ID: 26496380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist.
    Younis JS; Matilsky M; Radin O; Ben-Ami M
    Fertil Steril; 2001 Aug; 76(2):294-9. PubMed ID: 11476775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization.
    Scott RT; Navot D
    Fertil Steril; 1994 May; 61(5):880-5. PubMed ID: 8174725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.